KÜÇÜK HÜCRELİ AKCİĞER KANSERİNDE PROGNOSTİK NUTRİSYONEL İNDEKSİN PROGNOZ ÜZERİNE ETKİSİ: TEK MERKEZ DENEYİMİ

Amaç: Küçük hücreli akciğer kanseri hastalarında prognostik nutrisyonel indeks parametresinin genel sağkalım üzerine etkisiniaraştırmaktır.Materyal ve Metot: Kliniğimizde takip edilen 52 küçük hücreli akciğer kanseri hastasının dosyaları retrospektif olarak incelendi. Tanıanındaki albümin ve lenfosit değeri kullanılarak prognostik nutrisyonel indeks (PNİ) hesaplandı. PNİ ile genel sağkalım arasındaki ilişkiincelendi.Bulgular: Hastaların 47’si (%87) erkek, 5’i kadındı. Yaş ortancası 62.9 (48-82) idi. Ortanca PNİ değeri 45 idi. Median progresyonsuzsağkalım süresi 6.9 ay, median genel sağkalım süresi 8.7 ay idi.Çok değişkenli analizde, sınırlı evre hastalık ve PNİ≥45 olması genelsağkalım için bağımsız iyi prognostik faktör olarak saptandı. Genel sağ kalımla cinsiyet, yaş, LDH durumu arasında ilişki saptanmadı.Sonuç: Çalışmamızda prognostik nutriyonel indeks ve sınırlı evre hastalığın genel sağkalım açısından iyi prognostik bir faktör olduğunusaptadık.

The Effect of Prognostic Nutritional Index on Prognosis in Small Cell Lung Cancer: Single Center Experience

Aim: The aim of this study is to investigate the effect of prognostic nutritional index parameter on overall survival in small cell lung cancer patients. Materials and Methods: Fifty-two small cell lung cancer patients who were diagnosed in our clinic were reviewed retrospectively. Prognostic nutritional index (PNI) was calculated using albumin and lymphocyte value at the time of diagnosis. The relationship between PNI and overall survival was examined. Results: Of the 52 patients in our study, 47 were male and 5 were female. The median age was 62.9 years.The median PNI value was 45. Median progression-free survival was 6.9 months, median overall survival was 8.7 months. In the multivariate analysis, limited stage disease and PNI≥45 were found to be an independent good prognostic factor for overall survival. There was no relationship between overall survival and gender, age, and LDH status.

PDF

___

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. World Health Organization. International Agency for Research on Cancer, Section of Cancer Information. Cancer Incidence and Mortality Worldwide, 2008.
3. National comprehensive cancer Network. Clinical practice guidelines. Small cell lung cancer. Available at: may 5, 2015.
4. Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist 2010;15:187-195.
5. Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010;35:202-215.
6. Foster NR, Mandrekar SJ, Schild SE, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer treatment group trials. Cancer 2009; 115:2721-2731.
7. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-1574.
8. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20–37
9. Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810–6.
10. Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with oposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol. 2014;15(1):106–13.
11. Candido, J, Hagemann, T. Cancer-related inflammation. J Clin Immunol 2013; 33 Suppl 1: S79–84.
12. Sapienza, C, Issa, JP. Diet, nutrition, and cancer epigenetics. Annu Rev Nutr 2016; 36: 665–681.
13. Hirahara, N, Tajima, Y, Fujii, Y. Preoperative prognostic nutritional index predicts long-term surgical outcomes in patients with esophageal squamous cell carcinoma. World J Surg 2017; 42 (7): 2199–2208.
14. Sun, K, Chen, S, Xu, J. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2014; 140 (9): 1537–1549.
15. Yang, Y, Gao, P, Song, Y. The prognostic nutritional index is a predictive indicator of prognosis and postoperative complications in gastric cancer: a meta-analysis. Eur J Surg. Oncol. 2016
16. Eatrides J,Thompson Z, Lee JH, Bello C, Dalia S. Serum albümin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma. Ann Hematol. 2014.
17. Biswas B, Rastogi S, Khan SA, Shukla NK, Deo SV, Agarwala S, et al. Hypoalbuminaemia is an independent predictor of poor outcome in metastatic ewing’s sarcoma family of tumours: a single institutional experience of 150 cases treated with uniform chemotherapy protocol. Clin Oncol (R Coll Radiol). 2014
18. Du XJ, Tang LL, Mao YP, Sun Y, Zeng MS, Kang TB, et al. The pretreatment albumin to globulin ratio has predictive value for longterm mortality in nasopharyngeal carcinoma. PLoS One. 2014;9(4).
19. Li G, Gao J, Liu ZG, Tao YL, Xu BQ, Tu ZW, et al. Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: long-term outcomes of 512 patients from a single institution. Head Neck. 2014;36(5):660–6.
20. Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev. 2014;40(6):685–91.
21. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67(3):257–62.
22. Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology. 1988;8(2):385–401.
23. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.
24. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
25. Ceze N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E, et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 2011;68(5):1305–13.
26. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–91.
27. MaestuI, Pastor M, Gomez-Codina J, Aparicio J, Oltra A, Herranz C, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol. 1997;8(6):547–53.